Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)-Reference-Cited by-同舟云学术

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

Published:2010-03-03 Issue:8 Volume:12 Page:855-861
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:Neuro-Oncology

Author:

Iwamoto F. M.,Lamborn K. R.,Robins H. I.,Mehta M. P.,Chang S. M.,Butowski N. A.,DeAngelis L. M.,Abrey L. E.,Zhang W.-T.,Prados M. D.,Fine H. A.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Clinical Neurology,Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/12/8/855/3725937/noq025.pdf

Reference32 articles.

1. Malignant Gliomas in Adults

2. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

3. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

4. Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effects of the combination therapy of chemotherapy drugs on the fluctuations of genes involved in the TLR signaling pathway in glioblastoma multiforme therapy;Biomedicine & Pharmacotherapy;2024-08

2. Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment;Critical Reviews in Oncology/Hematology;2024-06

3. Glioblastoma Therapy: Past, Present and Future;International Journal of Molecular Sciences;2024-02-21

4. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial;BMC Cancer;2024-01-02

5. Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy;Current Neuropharmacology;2024-01